



OPEN ACCESS

EDITED AND REVIEWED BY
Muhammad Aslam,
University of Giessen, Germany

*CORRESPONDENCE
Lonny R. Levin,
✉ llevin@med.cornell.edu

SPECIALTY SECTION
This article was submitted to Cell
Physiology, a section of the journal
Frontiers in Physiology

RECEIVED 10 February 2023
ACCEPTED 21 February 2023
PUBLISHED 06 March 2023

CITATION
Rossetti T, Ferreira J, Ghanem L, Buck H,
Steegborn C, Myers RW, Meinke PT,
Levin LR and Buck J (2023),
Corrigendum: Assessing potency and
binding kinetics of soluble adenylyl
cyclase (sAC) inhibitors to maximize
therapeutic potential.
Front. Physiol. 14:1163389.
doi: 10.3389/fphys.2023.1163389

COPYRIGHT
© 2023 Rossetti, Ferreira, Ghanem, Buck,
Steegborn, Myers, Meinke, Levin and
Buck. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original author(s)
and the copyright owner(s) are credited
and that the original publication in this
journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential

Thomas Rossetti¹, Jacob Ferreira¹, Lubna Ghanem¹,
Hannes Buck¹, Clemens Steegborn², Robert W. Myers³,
Peter T. Meinke³, Lonny R. Levin^{1*} and Jochen Buck¹

¹Department of Pharmacology, Weill Cornell Medicine, New York, NY, United States, ²Department of Biochemistry, University of Bayreuth, Bayreuth, Germany, ³Tri-Institutional Therapeutics Discovery Institute, New York, NY, United States

KEYWORDS

soluble adenylyl cyclase, male contraceptive, residence time, drug development, picomolar potency, binding kinetics, lead optimization, SPR

A Corrigendum on

Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential

by Rossetti T, Ferreira J, Ghanem L, Buck H, Steegborn C, Myers RW, Meinke PT, Levin LR and Buck J (2022). *Front. Physiol.* 13:1013845. doi: 10.3389/fphys.2022.1013845







In the original article, there was an error in **Table 1** as published. In this table, the chemical structures of TDI-11861 and TDI-11155 were incorrect as the chloro and amino groups of the pyrimidine were drawn in the incorrect positions. In the correct chemical structures, the chloro and amino groups are located at the 4- and 2-positions, respectively. The corrected **Table 1** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 1 *In Vitro* Biochemical and Cellular Potency of sAC Inhibitors.

	sAC inhibitor structure	Standard assay IC ₅₀ (nM)	Subnanomolar assay IC ₅₀ (nM)	Cellular (4-4) IC ₅₀ (nM)
LRE1		3238	n/d	5266
TDI-10229		159	194	114
TDI-11155		11	11	16
TDI-11861		≤2.5	1.7	5
TDI-11893		≤2.5	1.7	19
TDI-11891		≤2.5	0.33	2.3